Recursion's blood vessel disorder drug meets main goal in mid-stage study (updated)

Recursion Pharmaceuticals

03/09/2024 13:21

(Adds details throughout)
       Sept 3 (Reuters) - Recursion Pharmaceuticals  RXRX.O 
said on Tuesday its experimental drug to treat a condition that
causes blood vessel malformation met the main goal of safety and
tolerability in a mid-stage study.
    However, shares of the company fell 6.6% in premarket
trading.
    The drug, REC-994, was being tested to treat cerebral
cavernous malformations, which refers to abnormal collections of
small blood vessels in the brain.
        Recursion said it plans to meet with the U.S. FDA to
discuss plans for an additional clinical study. 
  
        
  

 (Reporting by Mariam Sunny in Bengaluru; Editing by Alan
Barona)
 ((Mariam.ESunny@thomsonreuters.com))